Pharmacotherapy for obstructive sleep apnea - A systematic review and meta-analysis of randomized controlled trials

Yi-Chieh Lee,Chun-Ting Lu,Li-Pang Chuang,Li-Ang Lee,Tuan-Jen Fang,Wen-Nuan Cheng,Hsueh-Yu Li
DOI: https://doi.org/10.1016/j.smrv.2023.101809
IF: 11.401
2023-06-01
Sleep Medicine Reviews
Abstract:Continuous positive airway pressure is the first-line and gold-standard treatment for obstructive sleep apnea (OSA). Pharmacotherapy is not commonly used in treating OSA until recently. Combined noradrenergic and antimuscarinic agents have been clinically applied for OSA patients with variable results. This meta-analysis study aimed to investigate the efficacy of the combined regimen on OSA. A systematic literature search was performed up to November 2022 for the effects of the combined regimen on OSA. Eight randomized controlled trials were identified and systematically reviewed for meta-analysis. There were significant mean differences between OSA patients taking a combined regimen and placebo in apnea-hypopnea index (AHI) [mean difference (MD) -9.03 events/h, 95%CI (-16.22, -1.83 events/h; P = 0.01] and lowest oxygen saturation [MD 5.61%, 95% CI % (3.43, 7.80); P < 0.01]. Meta-regression showed that a higher proportion of male participants was associated with a greater reduction of AHI (p = 0.04). This study showed a positive but modest effect of pharmacotherapy in the reduction of OSA severity. The combination drugs are most applicable to male OSA patients based on their efficacy and pharmacological susceptibility. Pharmacotherapy may be applied as an alternative, adjunctive or synergistic treatment under careful consideration of its side effects.
neurosciences,clinical neurology
What problem does this paper attempt to address?